Completed PHASE3 NCT00312156

Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 1

Interventions insulin NPH insulin aspart insulin detemir

Updated 6 times since 2017 Last updated: Jan 26, 2017 Started: Aug 31, 2002 Primary completion: Aug 31, 2003 Completion: Aug 31, 2003

This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 1 and is currently completed. Novo Nordisk A/S leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Belfast, United Kingdom , Birmingham, United Kingdom , Bodø, Norway , Bree, Belgium , Caen, France , Dublin, Ireland , Edegem, Belgium , Eindhoven, Netherlands , Frankfurt, Germany and 32 more locations